Lipum AB Financials
| LIPUM Stock | SEK 18.00 2.80 13.46% |
Lipum |
Please note, the imprecision that can be found in Lipum AB's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Lipum AB. Check Lipum AB's Beneish M Score to see the likelihood of Lipum AB's management manipulating its earnings.
Lipum AB Stock Summary
Lipum AB competes with Ascelia Pharma, NextCell Pharma, Annexin Pharmaceuticals, AlzeCure Pharma, and Cantargia. Lipum AB , a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. The company was founded in 2010 and is headquartered in Ume, Sweden. Lipum AB is traded on Stockholm Stock Exchange in Sweden.| Instrument | Sweden Stock View All |
| Exchange | Stockholm Exchange |
| ISIN | SE0015660899 |
| Business Address | TvistevAegen 48C, Ume, |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.lipum.se |
| Phone | 46 9 03 40 34 30 |
| Currency | SEK - Swedish Kronor |
You should never invest in Lipum AB without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Lipum Stock, because this is throwing your money away. Analyzing the key information contained in Lipum AB's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Lipum AB Key Financial Ratios
There are many critical financial ratios that Lipum AB's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Lipum AB reports annually and quarterly.| Return On Equity | -1.81 | |||
| Return On Asset | -0.91 | |||
| Target Price | 22.0 | |||
| Z Score | 36.3 |
Lipum Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Lipum AB's current stock value. Our valuation model uses many indicators to compare Lipum AB value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lipum AB competition to find correlations between indicators driving Lipum AB's intrinsic value. More Info.Lipum AB is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Lipum AB's earnings, one of the primary drivers of an investment's value.Lipum AB Systematic Risk
Lipum AB's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Lipum AB volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Lipum AB correlated with the market. If Beta is less than 0 Lipum AB generally moves in the opposite direction as compared to the market. If Lipum AB Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Lipum AB is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Lipum AB is generally in the same direction as the market. If Beta > 1 Lipum AB moves generally in the same direction as, but more than the movement of the benchmark.
Lipum AB February 27, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Lipum AB help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Lipum AB. We use our internally-developed statistical techniques to arrive at the intrinsic value of Lipum AB based on widely used predictive technical indicators. In general, we focus on analyzing Lipum Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Lipum AB's daily price indicators and compare them against related drivers.
| Downside Deviation | 5.11 | |||
| Information Ratio | 0.0542 | |||
| Maximum Drawdown | 19.86 | |||
| Value At Risk | (7.75) | |||
| Potential Upside | 8.33 |
Additional Tools for Lipum Stock Analysis
When running Lipum AB's price analysis, check to measure Lipum AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lipum AB is operating at the current time. Most of Lipum AB's value examination focuses on studying past and present price action to predict the probability of Lipum AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lipum AB's price. Additionally, you may evaluate how the addition of Lipum AB to your portfolios can decrease your overall portfolio volatility.